Kornimate/medical-research-clean huggingface dataset:
effects of mirror therapy on lower extremity in cp children

Conditions: Cerebral Palsy

Summary: a non-progressive condition that harms the developing brain both during and after birth is cerebral palsy (cp). it is a multifaceted syndrome marked by abnormalities in movement and posture, along with concomitant sensory-motor, cognitive, and behavioral impairments and seizures. cp can be divided into three types based on neurological classification: spastic, athetoid, and ataxic, impairments in motor skills and posture are hallmarks of cerebral palsy. various strategies have been employed in motor skill improvement interventions. one of them, mirror-mediated treatment, works by stimulating mirror neurons in a specific region of the brain cortex. mirror-mediated therapy involves the patient observing movement of his or her own limb reflected in a mirror, which activates mirror neurons. the application of mirror treatment improved gait capacity by elevating physical perception and balance ability. the purpose of the study will be to evaluate the effects of mirror therapy in lower limb hemiplegic cerebral palsy.

a randomized controlled trial will be conducted to investigate the effects of mirror therapy in children with hemiplegic cerebral palsy. data will be collected at the national institute of rehabilitation medicine in islamabad following ethical clearance. 26 patients will be enrolled in the study based on inclusion criteria. patients will be randomly assigned into 2 equal groups for the study. children in the control group will receive conventional therapy for 60 minutes, while children in the experimental group will receive 30 minutes of mirror therapy and 30 minutes of conventional therapy, for 12 weeks, 3 days every week. the primary outcome will be measured by selective control assessment of lower extremity scale (scale), while the secondary outcome will be measured by the pediatric balance scale (pbs). all gait parameters (stride length, step length, step width, cadence and foot angle) will be measured before and after the application of intervention. data will be analyzed using spss 27.0.

Eligibility criteria:
inclusion criteria: * age 6-12 years. * motor tone of effected lower extremity is 1 to 2 according to modified ashworth scale. * patient with enough cognition to understand and follow instructions exclusion criteria: * patients with any other neurological illness affecting their lower extremities (e.g., ms, parkinson's, peripheral neuropathy). * patients with prior fractures of the lower limb (ankle or foot). * patients with other forms of musculoskeletal diseases such as severe arthritis, ankle surgery, leg length difference.

Keywords: lower limb, mirror therapy, conventional therapy, spastic cp
chronic pain and transcranial direct current stimulation in clinical settings

Conditions: Chronic Pain

Summary: physical exercises and transcranial direct current stimulation (tdcs) are both known to reduce chronic pain in structured laboratory studies. the aim of this study is to assess the efficacy of this combined treatment in clinical settings.

chronic pain patients who are going to the physiotherapy clinic to receive tdcs treatment sessions are evaluated in order to assess the efficacy of tdcs in clinical settings. physiotherapists prescribe physical exercises adapted to the patients conditions. patients performed their physical exercises every time they received a tdcs treatment, but were also recommended to continue their physical exercises program at home after completion of physiotherapy visits. concerning tdcs treatment, patients were encouraged to receive 1 tdcs session per day for 5 consecutive days.

Eligibility criteria:
inclusion criteria: * to have chronic pain exclusion criteria: * contraindication to tdcs

Keywords: transcranial direct current stimulation physical exercise physiotherapy clinical settings
effect of phytalgic in osteoarthritis (oa)

Conditions: Osteoarthritis

Summary: the objective of the study is to test the effects of a herbal supplement, phytalgic, on the symptoms of osteoarthritis of the knee or hip, in patients with oa using nsaids or analgesics on a regular basis.


Eligibility criteria:
inclusion criteria: * knee or hip osteoarthritis * regular nsaids/analgesic treatment * signed inform consent exclusion criteria: * incapacity to understand study * irregular nsaid treatment

Keywords: osteoarthritis, knee or hip
prevalence and burden of hepatitis d virus infection in china through preoperative examination test (predict study)

Conditions: Hepatitis D; Hepatitis B; Antibodies; Anti-D; RNA Virus Infections

Summary: in china, there is no recommendation for hepatitis d virus (hdv) screening, but the fact is estimated that one-third of the world's population of individuals with chronic hepatitis b virus (hbv) infection live in china while we do not know the prevalence of co-infection of hbv/hdv in china. so far, no nationwide study has been undertaken to evaluate the epidemiology of hepatitis d, on the other hand, reports of hdv infection rate in different regions of china are not consistent because of the different detection methods and detection objects. here, we plan to test hdv-ab/rna for 5000 hbsag reactive samples from 10 major tertiary hospital and to know the prevalence and disease burden of hdv in china.


Eligibility criteria:
inclusion criteria: 1. positive hbv surface antigen (hbsag) 2. age 18 yeas and above exclusion criteria: 1. severe cardiac, renal, respiratory, hematological, or psychiatric illness.
randomized controlled trial comparing efficacy and tolerance of four pediculicides

Conditions: Headlice Infections

Summary: the main goal of our randomized controlled trial with blinded observer will be to compare four pediculicide products acting mechanically, paranix spray, paranix lotion, paranix mousse and hedrin against a reference product acting chemically, prioderm, during a non-inferiority (20% equivalence). the randomization will be balanced every 10 families. the secondary objective will be to compare the lenticide efficacy of the products and their local tolerance and cosmetic acceptibility.


Eligibility criteria:
inclusion criteria: * subject-male or female, child \> 3 years and adult * pediculosis of scalp, confirmed by the identification of minimum 5 live lice with a fine-tooth comb * negative urine pregnancy test before inclusion for women of childbearing potential * use of a contraceptive method by hormonal contraceptives or iuds or tubal ligation or condoms for women of childbearing potential * subject agreeing to participate in the study with written informed consent for participation * written consent of both parents for the minor patients. exclusion criteria: * children under 3 years. * woman pregnant or lactating or without contraception * use of a pediculicide or lenticide treatment within 2 weeks before entry into the study * subject with known hypersensitivity to any component of the tested products * subject who participated in a clinical study in the 3 months prior to inclusion * ongoing treatment potentially interacting with the treatment under study (other pediculicide products) * subject undertreatment susceptible to influence the evaluation of the trial (including trimethoprim-sulfamethoxazole). * severe medical or psychiatric illness considered by the investigator as potentially dangerous to the subject or incompatible with the conduct of the study * asthma * subject unable for linguistic or psychiatric reasons to understand the information and give informed consent * subject refusing to give written consent * subject deprived of his liberty by administrative or judicial decision, or guardianship * patient hospitalized in a medical or social facility for another reason that biomedical research

Keywords: head lice
cardiac function and metabolism in young adults born premature (pet-mri)

Conditions: Infant,Premature

Summary: the purpose of this research is to determine the effect of premature birth on later heart function and metabolism.

the purpose of this study is to determine the effects of premature birth on cardiac function, cardiac metabolism, and oxidative stress in a cohort of young adults born prematurely using cardiac positron emission tomography/magnetic resonance imaging and mitochondrial respiration studies.

Eligibility criteria:
inclusion criteria: * national lung project cohort only- birth weight \<1500g and a gestational age \<36 weeks * adults born preterm (non-national lung project) only- gestational age ≤32 weeks or birth weight ≤ 3lbs 5oz * healthy controls only- no personal history of known cardiovascular or pulmonary disease exclusion criteria: * metabolic disorders that would affect fludeoxyglucose uptake * contraindications to positron emission tomography and/or magnetic resonance imaging * pregnancy, if a female of child-bearing potential * a personal history of type i or type ii diabetes

Keywords: premature adults premature premature lung function premature cardiac function mri pet
effect of deep brain stimulation on neuropsychiatric fluctuations in patients with parkinson's disease

Conditions: Parkinson's Disease (Disorder)

Summary: retrospective, monocentric, observational study designed to evaluate the effects of bilateral subthalamic nucleus deep brain stimulation (dbs stn) on neuropsychiatric fluctuations in patients with parkinson's disease (pd)

pre-operative versus 12-month follow-up analysis of changing in neuropsychiatric fluctuations scale (nfs) score in preoperative versus postoperative med off (during acute withdrawal of dopaminergic therapy) and med on (during super-liminal levodopa dose) conditions. postoperative evaluations are always performed with dbs turned on and stimulating (stim on)

Eligibility criteria:
inclusion criteria: * parkinson's disease * treatment with bilateral stn dbs * evaluation with nfs in both preoperative and 12 months post-surgery follow-up context exclusion criteria: * dbs for non pd patients * unilateral dbs or other dbs targets * patients not evaluated with nfs * patients with incomplete preoperative evaluation * patients who refused the use of their data

Keywords: dbs deep brain stimulation neuropsychiatric fluctuations nonmotor fluctuations scale
comparison of efficacy of mirror therapy vs mental imagery in reduction of phantom limb pain in akap

Conditions: Phantom Limb Pain

Summary: limb amputation results in many types of pain, including localized pain at the stump and projected pain experienced by the patient in the location where the amputated limb used to be, known as phantom limb pain (plp). the aim of this study is to determine the relative benefits of mirror therapy vs mental imagery in reduction of phantom limb pain. randomized clinical trial study design will be followed.


Eligibility criteria:
inclusion criteria: * both male and female gender with ages from 12 to 75 years (17). * individuals with a unilateral above-knee amputation (aka) at least 6 months prior to the study. * experiencing phantom limb pain at least 3 months (16). exclusion criteria: * history of neurological disorders affecting pain perception or motor function (e.g., stroke, spinal cord injury, brain injury). * uncontrolled diabetes or other medical conditions that could affect healing or participation in the study. * pregnancy or breastfeeding.
fluorescence imaging of adalimumab-680lt in inflammatory bowel disease

Conditions: Crohn Disease; Ulcerative Colitis

Summary: crohn's disease (cd) and ulcerative colitis (uc) are chronic inflammatory bowel diseases (ibd). adalimumab is a human monoclonal antibody against tnf-alpha, a pro-inflammatory cytokine that mediates the inflammatory response in ibd upon binding to the tnf receptors. primary non-response to adalimumab is high in both cd and uc. currently, there are no predictors of response to adalimumab and the actual mechanism of action has not yet been elucidated. to gain better understanding of the drug targeting of adalimumab in ibd, the university medical center groningen (umcg) developed fluorescently labeled adalimumab (adalimumab-680lt). this study aims to assess the safety and the optimal dose of adalimumab-680lt to visualize and potentially quantify the local drug concentration and predict treatment response in ibd patients using in vivo and ex vivo fluorescence molecular imaging (fmi).


Eligibility criteria:
inclusion criteria: * established ibd diagnosis (uc or cd) * active disease (clinically defined as at least mild activity using dedicated scoring indices and biochemically defined by a fecal calprotectin \> 60 µg/g, measured within the last 6 weeks before inclusion) * patients must be eligible for adalimumab therapy * clinical indication for an endoscopic procedure * age: 18 years or older * written informed consent * for female patients of premenopausal age with intact reproductive organs or who are less than 2 years postmenopausal, a negative pregnancy test must be available. exclusion criteria: * pregnancy or breast feeding * female patient of premenopausal age who does not use any reliable form of contraception at the time of adalimumab-680lt administration and the following 10 weeks. * medical or psychiatric conditions that compromise the patient's ability to give informed consent * prior anti-tnf therapy in the last 6 weeks before inclusion * active extra gastrointestinal manifestations of crohn's disease * previous treatment with adalimumab and detectable anti-adalimumab antibodies levels

Keywords: fluorescence molecular endoscopy inflammatory bowel disease adalimumab-680lt
stroke's gait pattern modifications of induced by repeated bti

Conditions: Effect of Repeated Botulinum Toxin Injection on Gait Pattern in Stroke Patients

Summary: chronic stroke patients exhibit gait pattern alterations which are mainly due to spasticity and treated with repetitive multifocal botulinum toxin injection(bti). several studies demonstrated that single bti-session in a single muscle of paretic lower limb(ll) improved kinematic gait parameters(gp) but surprisingly none of them assessed the effects of repetitive multifocal bti on patient's gait pattern and their duration. the aim was to evaluate the impact of repetitive multifocal bti-sessions on gp of chronic stroke patients. to that end, gait of patients has been compared using 3d-gait analysis after at least 2 consecutive bti sessions.

all the patients will be tretaed with bti . these injections will be performed under electrical stimulation control (\~5ma). the dose, the number of site of injection per muscle is at the discretion of the physician according to patients' needs and physicians' routine clinical practice. the dilution the most commonly used will depend on the type of bont-a (botox®, xeomin® or dysport®) and was 100 u for 2.5ml (botox® and xeomin®) or 500 u for 2.5 ml (dysport®).

Eligibility criteria:
inclusion criteria: -\>18 years * a single hemispheric cerebral vascular lesion more than 6 months previously * able to walk 10 meters without any assistance * having benefited of at least 2 consecutive bti sessions, second 3d gait analysis performed at least 3 months after the last bti. exclusion criteria: * patient's refusal to participate to the study * inability to read the selected text * inability to cooperate * no affiliation to social security

Keywords: botulinum toxin injection stroke 3d motion analysis gait pattern
controlled trial of 4-aminosalicylic acid in patients with small bowel crohn's disease

Conditions: Crohn's Disease

Summary: objectives: i. assess the efficacy and safety of 4-aminosalicylic acid in patients with active crohn's disease of the small bowel.

protocol outline: this is a randomized, placebo controlled, multicenter study. patients are randomized to receive either oral 4-aminosalicylic acid (4-asa) or placebo twice a day for 12 weeks. after 12 weeks patients who improved with 4-asa and those who received placebo are given the option of receiving 4-asa for an additional year. patients who were randomized to receive 4-asa and continue treatment after 12 weeks are followed every 3 months for 1 year. patients who were randomized to receive placebo and begin 4-asa therapy after 12 weeks are followed monthly for 3 months, then every 3 months for 1 year. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * active small bowel crohn's disease established by clinical evaluation and prior radiologic study, endoscopy, surgical findings and/or histopathology * crohn's disease activity index (cdai) must be between 150 and 450 * no ulcerative or infectious colitis or severe perianal disease --prior/concurrent therapy-- * biologic therapy: not specified * chemotherapy: stable dose of no greater than 20 mg per day of prednisone allowed * endocrine therapy: no immunosuppressive drugs within the past 3 months no concurrent immunosuppressive drugs * radiotherapy: not specified * surgery: no impending surgery no prior ileostomy or colostomy * other: no 5-aminosalicylates within the past 2 weeks no concurrent 5-aminosalicylates no concurrent metronidazol or ciprofloxacin --patient characteristics-- * age: 18 to 80 * performance status: ambulatory * hematopoietic: not specified * hepatic: no hepatic disease * renal: no renal disease * other: not pregnant (negative pregnancy test required) fertile patients must use effective contraception no documented salicylate allergy

Keywords: crohn's disease gastrointestinal disorders rare disease
smartphone-based virtual reality exposure and standard relaxation training for anxiety on an inpatient psychiatric unit

Conditions: Anxiety; Pain

Summary: the purpose of this study is to compare a smartphone-based virtual reality exposure with standard relaxation training for anxiety and associated symptoms (including pain) on an inpatient psychiatric unit, and whether patients find it usable and beneficial.

the study is open only to inpatients on a specific mayo clinic rochester psychiatric hospital unit, the mood disorders unit. two different techniques for reducing anxiety will be tried. the first time patients report anxiety, they will be asked to listen to a 15 minute audio cd guiding them through relaxation strategies. the second time patients are anxious, they will be given a cardboard vr goggle set and will view 15 minutes of unguided vr. before and after each session, they will fill out a short survey of anxiety and related symptoms (including pain ratings) and their reaction to each technique. they will be asked to try each technique at least once during your hospital stay.

Eligibility criteria:
inclusion criteria: - hospitalized on inpatient mayo clinic mood disorders psychiatric unit (generose 3w). exclusion criteria: * inability to understand english. * patients with primary substance use disorders, primary psychotic disorders, major neurocognitive disorders and active self-harm behaviors and seizure disorders
cscc_asc therapy in patients with severe heart failure

Conditions: Heart Failure

Summary: the present aim is to perform at small clinical safety trial in heart failure patients with allogeneic adipose tissue derived mesenchymal stem cells.

patients with heart failure will be treated with culture expanded adipose tissue derived mesenchymal stem cells from healthy donors stored in nitrogen until use. the cells will be injected directly into the myocardium using the noga xp method. the patients will be followed for 6 months for safety and efficacy registration.

Eligibility criteria:
inclusion criteria: 1. 30 to 80 years of age 2. signed informed consent 3. chronic stable ihd 4. hf (nyha ii-iii) 5. lvef ≤45% 6. maximal tolerable angina and heart failure medication 7. medication unchanged two months prior to inclusion 8. angiography within six months of inclusion 9. no option for percutaneous coronary intervention (pci) or coronary artery bypass graft (cabg) 10. patients who have had pci or cabg within six months of inclusion must have a new angiography less than one month before inclusion or at least four months after the intervention to rule out early restenosis 11. patients cannot be included until six months after implantation of a cardiac resynchronisation therapy device exclusion criteria: 1. heart failure (nyha i or iv) 2. acute coronary syndrome with elevation of ckmb or troponins, stroke or transitory cerebral ischemia within six weeks of inclusion 3. other revascularisation treatment within four months of treatment 4. moderate to severe valvular disease or valvular disease with option for valvular surgery 5. diminished functional capacity for other reasons such as: coronary obstructive pulmonary disease (copd) with forced expiratory volume (fev) \<1 l/min, moderate to severe claudication or morbid obesity 6. clinical significant anaemia, leukopenia, leukocytosis or thrombocytopenia 7. clinically significant abnormal prothrombin or partial thromboplastin time or anticoagulation treatment that cannot be paused during cell injections 8. patients with reduced immune response or treated with immunosuppressive medication 9. history with malignant disease within five years of inclusion or suspected malignity - except treated skin cancer other than melanoma 10. pregnant women 11. other experimental treatment within four weeks of baseline tests 12. participation in another intervention trial
rehabilitation in pulmonary sarcoidosis: a prospective study

Conditions: Pulmonary Sarcoidosis

Summary: sarcoidosis is a heterogeneous multisystem disorder of unknown etiology which often presents with bilateral hilar lymphadenopathy, pulmonary infiltration and ocular and skin lesions. in addition to possible changes in forced vital capacity (fvc) and carbon monoxide transfer factor (tlco), a higher prevalence of clinical depression, reduced health status and exercise intolerance have been observed in patients with sarcoidosis. reduced health status has been related to decreased pulmonary function, depressive symptoms, and to respiratory muscle weakness. exercise capacity is believed to be limited by dyspnea, an insufficient heart rate response, decreased arterial oxygen tension during exercise, excessive and inefficient ventilation and by respiratory muscle weakness. in the past, exercise capacity was shown to be limited by skeletal muscle weakness in patients with chronic pulmonary or cardiac disease. 67% of the sarcoidosis patients studied by miller et al terminated their peak exercise test due to "leg complaints". skeletal muscle weakness is therefore still assumed to be present in patients with sarcoidosis. treatment with oral corticosteroids, clinical symptoms of depression, myositis, self-reported complaints of fatigue and high circulating levels of tumour necrosis factor-α (tnf-α) are all present in patients with sarcoidosis and can all affect skeletal muscle force and exercise capacity. additionally, low levels of circulating insulin-like growth factor i (igf-i), which can be induced by high levels of tnf-α, and high circulating levels of interleukin (il)-6 and il-8 (cxcl8) have been associated with skeletal muscle weakness. these interleukins are part of the current concept of the immunopathogenesis of sarcoidosis16 and may be raised in patients with stable sarcoidosis. recent studies have shown that pulmonary rehabilitation program can lead to improve in the health status and anxiety among patients with chronic obstructive lung disease .however, no study has evaluated the role of pulmonary rehabilitation among patients with sarcoidosis.


Eligibility criteria:
inclusion criteria: * stable pulmonary sarcoidosis with no change in medication during the last 3 months. exclusion criteria: * any significant other pulmonary and\\or co-morbidity that can affect exercise tolerance. * chronic steroid treatment more than 5 mg/day. * previous lung surgery. * advanced heart failure (nyha iii-iv ) * malignancy during the last 3 years

Keywords: stable pulmonary sarcoidosis with no change in medication during the last 3 months/